Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy

Drablos, 2004, Alkylation damage in DNA and RNA-repair mechanisms and medical significance, DNA Repair (Amst), 3, 1389, 10.1016/j.dnarep.2004.05.004 Dolan, 1998, O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings, J Clin Oncol, 16, 1803, 10.1200/JCO.1998.16.5.1803 Friedman, 2000, Can O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic?, Clin Cancer Res, 6, 2967 Schilsky, 2000, Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer, Clin Cancer Res, 6, 3025 Spiro, 1999, O6-Benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair, Cancer Res, 59, 2402 Fishel, 2003, Enhancement of platinum-induced cytotoxicity by O6-benzylguanine, Mol Cancer Ther, 2, 633 Prados, 2000, Future directions in the treatment of malignant gliomas with temozolomide, Semin Oncol, 27, 41 Kokkinakis, 2001, Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice, Cancer Res, 61, 4017 Chapman, 1999, Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma, J Clin Oncol, 17, 2745, 10.1200/JCO.1999.17.9.2745 Lens, 2003, Systemic chemotherapy in the treatment of malignant melanoma, Expert Opin Pharmacother, 4, 2205, 10.1517/14656566.4.12.2205 Berger, 1993, Alkylating agents, 400 Fuller, 1983, Diagnosis and management of Hodgkin’s disease in the adult, Cancer, 51, 2469, 10.1002/1097-0142(19830615)51:12+<2469::AID-CNCR2820511315>3.0.CO;2-4 Weiss, 1982, Streptozocin: a review of its pharmacology, efficacy, and toxicity, Cancer Treat Rep, 66, 427 Tong, 1982, Formation of the cross-link 1-[N3-deoxycytidyl],2-[N1-deoxyguanosinyl]ethane in DNA treated with N,N′-bis(2-chloroethyl)-N-nitrosourea, Cancer Res, 42, 3102 Pauly, 1994, Response of repair-competent and repair-deficient Escherichia coli to three O6-substituted guanines and involvement of methyl-directed mismatch repair in the processing of O6-methylguanine residues, Biochemistry, 33, 9169, 10.1021/bi00197a020 Caporali, 2004, DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system, Mol Pharmacol, 66, 478 Mitra, 1993, Regulation of repair of alkylation damage in mammalian genomes, Prog Nucl Acid Res Mol Biol, 44, 109, 10.1016/S0079-6603(08)60218-4 Pegg, 1995, Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N′-bis(2-chloroethyl)-N-nitrosourea, Biochem Pharmacol, 50, 1141, 10.1016/0006-2952(95)00249-Y Dolan, 1988, Use of a dodecadeoxynucleotide to study repair of the O4-methylthymine lesion, Mutat Res, 193, 131 Margison, 2003, Variability and regulation of O6-alkylguanine-DNA alkyltransferase, Carcinogenesis, 24, 625, 10.1093/carcin/bgg005 Gerson, 1986, Comparison of O6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues, Carcinogenesis, 7, 745, 10.1093/carcin/7.5.745 Redmond, 1991, Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors, Cancer Res, 51, 2092 Zaidi, 1996, Quantitative immunohistochemical estimates of O6-alkylguanine-DNA alkyltransferase expression in normal and malignant human colon, Clin Cancer Res, 2, 577 Lee, 1992, Immunohistological examination of the inter-and intracellular distribution of O6-alkylguanine DNA-alkyltransferase in human liver and melanoma, Br J Cancer, 66, 355, 10.1038/bjc.1992.270 Moriwaki, 1992, O6-alkylguanine-DNA alkyltransferase activity in human malignant melanoma, J Dermatol Sci, 4, 6, 10.1016/0923-1811(92)90049-H Bobola, 2001, O6-Methylguanine-DNA methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics, Clin Cancer Res, 7, 613 Chen, 1999, Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients, Can J Neurol Sci, 26, 104, 10.1016/S0022-510X(00)00346-4 Silber, 1999, O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy, Clin Cancer Res, 5, 807 Kokkinakis, 1997, Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents, Cancer Res, 57, 5360 Citron, 1993, O6-methylguanine-DNA methyltransferase in human normal and malignant lung tissues, Cancer Invest, 11, 258, 10.3109/07357909309024850 Gerson, 2002, Clinical relevance of MGMT in the treatment of cancer, J Clin Oncol, 20, 2388, 10.1200/JCO.2002.06.110 Belanich, 1996, Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine, Cancer Res, 56, 783 Friedman, 1992, Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme, J Natl Cancer Inst, 84, 1926, 10.1093/jnci/84.24.1926 Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, 352, 997, 10.1056/NEJMoa043331 Rasimas, 2003, DNA-binding mechanism of O6-alkylguanine-DNA alkyltransferase. Effects of protein and DNA alkylation on complex stability, J Biol Chem, 278, 7973, 10.1074/jbc.M211854200 Daniels, 2000, Conserved structural motifs governing the stoichiometric repair of alkylated DNA by O6 -alkylguanine-DNA alkyltransferase, Mutat Res, 460, 151, 10.1016/S0921-8777(00)00024-0 Kanugula, 2001, Novel DNA repair alkyltransferase from Caenorhabditis elegans, Environ Mol Mutagen, 38, 235, 10.1002/em.1077 Moore, 1994, Crystal structure of a suicidal DNA repair protein: the Ada O6-methylguanine-DNA methyltransferase from E. coli, EMBO J, 13, 1495, 10.1002/j.1460-2075.1994.tb06410.x Kanugula, 2003, Alkylation damage repair protein O6-alkylguanine-DNA alkyltransferase from the hyperthermophiles Aquifex aeolicus and Archaeoglobus fulgidus, Biochem J, 375, 449, 10.1042/bj20030809 Daniels, 2000, Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding, EMBO J, 19, 1719, 10.1093/emboj/19.7.1719 Wibley, 2000, Crystal structure of the human O6-alkylguanine-DNA alkyltransferase, Nucl Acids Res, 28, 393, 10.1093/nar/28.2.393 Huffman, 2005, DNA base damage recognition and removal: new twists and grooves, Mutat Res, 577, 55, 10.1016/j.mrfmmm.2005.03.012 Daniels, 2004, DNA binding and nucleotide flipping by the human DNA repair protein AGT, Nat Struct Mol Biol, 11, 714, 10.1038/nsmb791 Fried, 1996, DNA binding mechanism of O6-alkylguanine-DNA alkyltransferase: stoichiometry and effects of DNA base composition and secondary structure on complex stability, Biochemistry, 35, 15295, 10.1021/bi960971k Verdine, 1997, How do DNA repair proteins locate damaged bases in the genome?, Chem Biol, 4, 329, 10.1016/S1074-5521(97)90123-X Duguid, 2003, How do DNA repair proteins locate potential base lesions? a chemical crosslinking method to investigate O6-alkylguanine-DNA alkyltransferases, Chem Biol, 10, 827, 10.1016/j.chembiol.2003.08.007 Dolan, 1990, Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents, Proc Natl Acad Sci USA, 87, 5368, 10.1073/pnas.87.14.5368 Esteller, 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, N Engl J Med, 343, 1350, 10.1056/NEJM200011093431901 Jaeckle, 1998, Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study, J Clin Oncol, 16, 3310, 10.1200/JCO.1998.16.10.3310 Friedman, 1998, Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma, J Clin Oncol, 16, 3570, 10.1200/JCO.1998.16.11.3570 Middleton, 1998, O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma, Br J Cancer, 78, 1199, 10.1038/bjc.1998.654 Dolan, 1985, Exposure of HeLa cells to O6-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents, Biochem Biophys Res Commun, 132, 178, 10.1016/0006-291X(85)91004-6 Dolan, 1985, Reduction of O6-alkylguanine-DNA alkyltransferase activity in HeLa cells treated with O6-alkylguanines, Cancer Res, 45, 6413 Karran, 1985, Proc Natl Acad Sci USA, 82, 5285, 10.1073/pnas.82.16.5285 Karran, 1985, The cytotoxic and mutagenic effects of alkylating agents on human lymphoid cells are caused by different DNA lesions, Carcinogenesis, 6, 789, 10.1093/carcin/6.5.789 Yarosh, 1986, Inactivation of O6-methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by O6-methylguanine as a free base, Cancer Res, 46, 1663 Gerson, 1989, Modulation of human lymphocyte O6-alkylguanine-DNA alkyltransferase by streptozotocin in vivo, Cancer Res, 49, 3134 Pieper, 1991, Effects of streptozotocin/bis-chloroethylnitrosourea combination therapy on O6-methylguanine DNA methyltransferase activity and mRNA levels in HT-29 cells in vitro, Cancer Res, 51, 1581 Zeller, 1986, More than additive toxicity of the combination of 1-methyl-1-nitrosourea plus 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat, Cancer Res, 46, 1714 Gerson, 1988, Modulation of nitrosourea resistance in myeloid leukemias, Blood, 71, 1487, 10.1182/blood.V71.5.1487.1487 Tserng, 2003, Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine, J Clin Pharmacol, 43, 881, 10.1177/0091270003256060 Dolan, 1989, Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine, Cancer Chemother Pharmacol, 25, 103, 10.1007/BF00692348 Marathi, 1994, Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo, Biochem Pharmacol, 48, 2127, 10.1016/0006-2952(94)90514-2 Marathi, 1994, Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2′-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity, Cancer Res, 54, 4371 Marathi, 1993, Prolonged depletion of O6-methylguanine DNA methyltransferase activity following exposure to O6-benzylguanine with or without streptozotocin enhances 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity in vitro, Cancer Res, 53, 4281 Dolan, 1991, Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents, Cancer Res, 51, 3367 Dolan, 1991, Comparison of the inactivation of mammalian and bacterial O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine and O6-methylguanine, Carcinogenesis, 12, 2305, 10.1093/carcin/12.12.2305 Dolan, 1990, Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, Cancer Commun, 2, 371, 10.3727/095535490820873985 Moschel, 1984, Substituent-induced effects on the stability of benzylated guanosines: model systems for the factors influencing the stability of carcinogen-modified nucleic acids, J Org Chem, 49, 363, 10.1021/jo00176a028 Streitweiser, 1962 Baer, 1993, Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells, Br J Cancer, 67, 1299, 10.1038/bjc.1993.241 Dolan, 1997, Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents, Adv Drug Delivery Rev, 26, 105, 10.1016/S0169-409X(97)00028-8 Dolan, 1997, O6-benzylguanine and its role in chemotherapy, Clin Cancer Res, 3, 837 Magull-Seltenreich, 1995, Sensitization of human colon tumour cell lines to carmustine by depletion of O6-alkylguanine-DNA alkyltransferase, J Cancer Res Clin Oncol, 121, 225, 10.1007/BF01366966 Pegg, 1993, Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine, Biochemistry, 32, 11998, 10.1021/bi00096a009 Pegg, 2000, Repair of O6-alkylguanine by alkyltransferases, Mutat Res, 462, 83, 10.1016/S1383-5742(00)00017-X Pegg, 1991, Use of antibodies to human O6-alkylguanine-DNA alkyltransferase to study the content of this protein in cells treated with O6- benzylguanine or N-methyl-N′-nitro-N-nitrosoguanidine, Carcinogenesis, 12, 1679, 10.1093/carcin/12.9.1679 Crone, 1994, Mutations in human O6-alkylguanine-DNA alkyltransferase imparting resistance to O6-benzylguanine, Cancer Res, 54, 6221 Ayi, 1994, A method for simultaneous identification of human active and active-site alkylated O6-methylguanine-DNA methyltransferase and its possible application for monitoring human exposure to alkylating carcinogens, Cancer Res, 54, 3726 Oh, 1996, Conformational change in human DNA repair enzyme O6-methylguanine-DNA methyltransferase upon alkylation of its active site by SN1 (indirect-acting) and SN2 (direct-acting) alkylating agents: breaking a “salt-link”, Biochemistry, 35, 12259, 10.1021/bi9603635 Srivenugopal, 1996, Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea, Biochemistry, 35, 1328, 10.1021/bi9518205 Liu, 1996, Differential sensitivity of human and mouse alkyltransferase to O6-benzylguanine using a transgenic model, Cancer Res, 56, 1880 Elder, 1994, Differential inactivation of mammalian and Escherichia coli O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine, Biochem J, 298, 231, 10.1042/bj2980231 Crone, 1993, A single amino acid change in human O6-alkylguanine-DNA alkyltransferase decreasing sensitivity to inactivation by O6-benzylguanine, Cancer Res, 53, 4750 Chae, 1994, Substituted O6-benzylguanine derivatives and their inactivation of human O6-alkylguanine-DNA alkyltransferase, J Med Chem, 37, 342, 10.1021/jm00029a005 Chae, 1995, 8-Substituted O6-benzylguanine, substituted 6(4)-(benzyloxy)pyrimidine, and related derivatives as inactivators of human O6-alkylguanine-DNA alkyltransferase, J Med Chem, 38, 359, 10.1021/jm00002a018 Griffin, 2000, Resistance-modifying agents. 8. Inhibition of O6-alkylguanine-DNA alkyltransferase by O6-alkenyl-, O6-cycloalkenyl-, and O6-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O6-(1-cyclopentenylmethyl)guanine, J Med Chem, 43, 4071, 10.1021/jm000961o Moschel, 1992, Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase, J Med Chem, 35, 4486, 10.1021/jm00101a028 Ewesuedo, 2001, Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice, Cancer Chemother Pharmacol, 47, 63, 10.1007/s002800000202 Kokkinakis, 1999, Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2′-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea, Clin Cancer Res, 5, 3676 Kokkinakis, 2000, Potentiation of BCNU antitumor efficacy by 9-substituted O6-benzylguanines. Effect of metabolism, Cancer Chemother Pharmacol, 45, 69, 10.1007/PL00006746 Long, 2000, Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates, Clin Cancer Res, 6, 3662 Kokkinakis, 1996, Mechanism of depletion of O6-methylguanine-DNA methyltransferase activity in rat tissues by O6-Benzyl-2′-deoxyguanosine. Role of metabolism, In Vivo, 10, 297 Schold, 1996, Treatment of human brain tumor xenografts with O6-benzyl-2′-deoxyguanosine and BCNU, Cancer Res, 56, 2076 Kokkinakis, 2003, Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2′-deoxyguanosine, Clin Cancer Res, 9, 3801 Middleton MR, Kelly J, McElhinney RS, McMurry TBH, Margison GP. O6-(4-bromothenyl)-guanine (4BTG) is an effective inactivator of O6-alkylguanine-DNA alkyltransferase (ATase), and improves the therapeutic index of temozolomide (TMZ) to a greater extent than O6-benzylguanine (BeG). American Association for Cancer Research, Philadelphia, PA, 1999. Nelson, 2004, 2-amino-O4-benzylpteridine derivatives: potent inactivators of O6-alkylguanine-DNA alkyltransferase, J Med Chem, 47, 3887, 10.1021/jm049758+ de Nonancourt-Didion, 2001, Overexpression of folate binding protein alpha is one of the mechanism explaining the adaptation of HT29 cells to high concentration of methotrexate, Cancer Lett, 171, 139, 10.1016/S0304-3835(01)00552-3 Ladino, 1997, Folate-maytansinoids: target-selective drugs of low molecular weight, Int J Cancer, 73, 859, 10.1002/(SICI)1097-0215(19971210)73:6<859::AID-IJC16>3.0.CO;2-# Ross, 1994, Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications, Cancer, 73, 2432, 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S Wang, 1997, Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical, Bioconjug Chem, 8, 673, 10.1021/bc9701297 Middleton, 2000, O6 -(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts, Int J Cancer, 85, 248, 10.1002/(SICI)1097-0215(20000115)85:2%3C248::AID-IJC16%3E3.0.CO;2-V Middleton, 2002, Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model, Int J Cancer, 100, 615, 10.1002/ijc.10532 Middleton, 2003, Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway, Lancet Oncol, 4, 37, 10.1016/S1470-2045(03)00959-8 Turriziani, 2006, O6 -(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6 -alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro, Pharmacol Res, 53, 317, 10.1016/j.phrs.2005.12.001 Barvaux, 2004, Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase, Mol Cancer Ther, 3, 1215, 10.1158/1535-7163.1215.3.10 Barvaux, 2004, Dual repair modulation reverses Temozolomide resistance in vitro, Mol Cancer Ther, 3, 123, 10.1158/1535-7163.123.3.2 Clemons, 2005, O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts, Br J Cancer, 93, 1152, 10.1038/sj.bjc.6602833 Woolford, 2006, The P140K mutant of human O6-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O6-(4-bromothenyl)guanine, J Gene Med, 8, 29, 10.1002/jgm.816 Futscher, 1989, Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells, Cancer Commun, 1, 65, 10.3727/095535489820875444 Kreklau, 1999, Prolonged inhibition of O6-methylguanine DNA methyltransferase in human tumor cells by O6-benzylguanine in vitro and in vivo, J Pharmacol Exp Ther, 291, 1269 Dolan, 1993, Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer, Cancer Chemother Pharmacol, 32, 221, 10.1007/BF00685839 Felker, 1993, Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea, Cancer Chemother Pharmacol, 32, 471, 10.1007/BF00685892 Gerson, 1993, Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone, Biochem Pharmacol, 45, 483, 10.1016/0006-2952(93)90086-C Mitchell, 1992, Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation, Cancer Res, 52, 1171 Rhines, 2000, O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma, Cancer Res, 60, 6307 Kreklau, 2001, Comparison of single- versus double-bolus treatments of O6-benzylguanine for depletion of O6-methylguanine DNA methyltransferase (MGMT) activity in vivo: development of a novel fluorometric oligonucleotide assay for measurement of MGMT activity, J Pharmacol Exp Ther, 297, 524 Wedge, 1996, 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity, Br J Cancer, 74, 1030, 10.1038/bjc.1996.485 Wedge, 1996, O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU, Br J Cancer, 73, 1049, 10.1038/bjc.1996.203 Wedge, 1997, Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model, Cancer Chemother Pharmacol, 40, 266, 10.1007/s002800050657 Margison, 2005, Quantitative trait locus analysis reveals two intragenic sites that influence O6-alkylguanine-DNA alkyltransferase activity in peripheral blood mononuclear cells, Carcinogenesis, 26, 1473, 10.1093/carcin/bgi087 Xu-Welliver, 1999, Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine, Biochem Pharmacol, 58, 1279, 10.1016/S0006-2952(99)00216-6 Xu-Welliver, 1999, Alteration of the conserved residue tyrosine-158 to histidine renders human O6-alkylguanine-DNA alkyltransferase insensitive to the inhibitor O6-benzylguanine, Cancer Res, 59, 1514 Xu-Welliver, 2000, Point mutations at multiple sites including highly conserved amino acids maintain activity, but render O6-alkylguanine-DNA alkyltransferase insensitive to O6-benzylguanine, Biochem J, 347, 519, 10.1042/0264-6021:3470519 Wu, 1999, Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer, Clin Cancer Res, 5, 209 Mijal, 2004, The repair of the tobacco specific nitrosamine derived adduct O6-[4-Oxo-4-(3-pyridyl)butyl]guanine by O6-alkylguanine-DNA alkyltransferase variants, Chem Res Toxicol, 17, 424, 10.1021/tx0342417 Xu-Welliver, 1998, Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine, Cancer Res, 58, 1936 Davis, 1999, Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy, Hum Gene Ther, 10, 2769, 10.1089/10430349950016500 Gerson, 1996, Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU, Blood, 88, 1649, 10.1182/blood.V88.5.1649.1649 Licht, 1997, In vivo drug-selectable genes: a new concept in gene therapy, Stem Cells, 15, 104, 10.1002/stem.150104 Chinnasamy, 2004, Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide, Hum Gene Ther, 15, 758, 10.1089/1043034041648417 Davis, 1997, Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea, Cancer Res, 57, 5093 Koc, 1999, DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts, Hum Gene Ther, 10, 1021, 10.1089/10430349950018418 Reese, 1996, Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea, Proc Natl Acad Sci USA, 93, 14088, 10.1073/pnas.93.24.14088 Reese, 1999, Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide, Clin Cancer Res, 5, 163 Chinnasamy, 1998, Chemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferase, Gene Ther, 5, 842, 10.1038/sj.gt.3300699 Berg, 1995, Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate, Cancer Res, 55, 4606 Dolan, 1994, Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase, Cancer Res, 54, 5123 Roy, 1995, Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes, Drug Metab Dispos, 23, 1394 Roy, 1995, Human liver oxidative metabolism of O6-benzylguanine, Biochem Pharmacol, 50, 1385, 10.1016/0006-2952(95)02019-5 Neville, 2004, Pharmacokinetics of O6-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study, Clin Cancer Res, 10, 5072, 10.1158/1078-0432.CCR-03-0123 Friedman, 2000, Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma, J Clin Oncol, 18, 3522, 10.1200/JCO.2000.18.20.3522 Gajewski, 2005, Phase II trial of O6-benzylguanine and BCNU in advanced melanoma, Clin Cancer Res, 11, 7861, 10.1158/1078-0432.CCR-05-0060 Page, 1994, Preclinical toxicology of O6-benzylguanine (NSC-637037) and BCNU (Carmustine NSC-409962) in male and female beagle dogs, Proc Am Assoc Cancer Res, 35, 328 Rogers, 1994, Preclinical toxicology and pharmacokinetics of O6-benzylguanine (NSC-637037) in mice and dogs, Proc Am Assoc Cancer Res, 35, 328 Dolan, 2002, Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors, Clin Cancer Res, 8, 2519 Schold, 2004, O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas, Neurooncology, 6, 28 Brem, 1995, Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group, Lancet, 345, 1008, 10.1016/S0140-6736(95)90755-6 Weingart J et al. Phase I trial of Gliadel™ Plus continuous infusion of intravenous O6-benzylguanine in patients with recurrent malignant glioma: A new approaches to brain tumor therapy CNS Consortium Trial, 2006. Quinn, 2005, Phase I Trial of Temodar Plus O6-BG in Glioma, J Clin Oncol, 23, 7178, 10.1200/JCO.2005.06.502 Aoki, 2003, A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme, Int J Clin Oncol, 8, 301, 10.1007/s10147-003-0339-3 Warren, 2005, Phase I O6 -BG/TMZ in children with solid tumors, J Clin Oncol, 23, 7646, 10.1200/JCO.2005.02.0024 Quinn, 2002, Phase II trial of carmustine plus O6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma, J Clin Oncol, 20, 2277, 10.1200/JCO.2002.09.084 Kartalou, 2001, Mechanisms of resistance to cisplatin, Mutat Res, 478, 23, 10.1016/S0027-5107(01)00141-5 Fishel, 2005, Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine, Cancer Chemother Pharmacol, 55, 333, 10.1007/s00280-004-0901-3 Zhang, 2001, Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms, Mol Pharmacol, 59, 837, 10.1124/mol.59.4.837 Grant, 2003, The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy, Drug Resist Update, 6, 15, 10.1016/S1368-7646(02)00141-3 Kim, 2003, Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA, Cancer Res, 63, 7291 Senderowicz, 2003, Cell cycle modulators for the treatment of lung malignancies, Clin Lung Cancer, 5, 158, 10.3816/CLC.2003.n.028 Arris, 2000, Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles, J Med Chem, 43, 2797, 10.1021/jm990628o Fishel, 2005, Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity, J Pharmacol Exp Ther, 312, 206, 10.1124/jpet.104.073924 Fishel, 2005, Role of GADD34 in modulation of cisplatin cytotoxicity, Biochem Pharmacol, 71, 239, 10.1016/j.bcp.2005.10.039 Mandic, 2003, Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling, J Biol Chem, 278, 9100, 10.1074/jbc.M210284200 Ryan CW, Dolan ME, Brockstein BB, et al. A phase II trial of O(6)-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol. Available online 7 March 2006.